The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Since its launch in 2015, it has been prescribed to more than 200,000 patients globally. The drug is currently approved for use in both men and women, expanding its market potential. Despite facing ...

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 ...

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy “PATINA is the ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

(RTTNews) - Pfizer Inc. (PFE), on Thursday, announced positive results from the Phase 3 PATINA trial, evaluating the addition of IBRANCE for treating metastatic breast cancer. The trial, sponsored by ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole ...

Three sets of trial data to be presented at the annual American Society of Clinical Oncology (ASCO) meeting this weekend could shake up breast cancer treatment—and are therefore closely followed by ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...